{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:28:28Z","timestamp":1772814508519,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,11,1]]},"abstract":"<jats:p> PURPOSE: PC-SPES is an herbal supplement for which there are anecdotal reports of anti\u2013prostate cancer activity. This phase II study was undertaken to assess the efficacy and toxicity of PC-SPES in prostate cancer patients. <\/jats:p><jats:p> PATIENTS AND METHODS: Thirty-three patients with androgen-dependent prostate cancer (ADPCa) and 37 patients with androgen-independent prostate cancer (AIPCa) were treated with PC-SPES at a dose of nine capsules daily. Clinical outcome was assessed with serial serum prostate-specific androgen (PSA) level measurement and imaging studies. <\/jats:p><jats:p> RESULTS: One hundred percent of ADPCa patients experienced a PSA decline of \u2265 80%, with a median duration of 57+ weeks. No patient has developed PSA progression. Thirty-one patients (97%) had declines of testosterone to the anorchid range. Two ADPCa patients had positive bone scans; both improved. One patient with a bladder mass measurable on computed tomography scan experienced disappearance of this mass. Nineteen (54%) of 35 AIPCa patients had a PSA decline of \u2265 50%, including eight (50%) of 16 patients who had received prior ketoconazole therapy. Median time to PSA progression was 16 weeks (range, 2 to 69+ weeks). Of 25 patients with positive bone scans, two had improvement, seven had stable disease, 11 had progressive disease, and five did not have a repeat bone scan because of PSA progression. Severe toxicities included thromboembolic events (n = 3) and allergic reactions (n = 3). Other frequent toxicities included gynecomastia\/gynecodynia, leg cramps, and grade 1 or 2 diarrhea. <\/jats:p><jats:p> CONCLUSION: PC-SPES seems to have activity in the treatment of both ADPCa and AIPCa and has acceptable toxicity. Further study is required to determine whether its effects exceed those expected with estrogen therapy. <\/jats:p>","DOI":"10.1200\/jco.2000.18.21.3595","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:46:41Z","timestamp":1487918801000},"page":"3595-3603","source":"Crossref","is-referenced-by-count":148,"title":["Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer"],"prefix":"10.1200","volume":"18","author":[{"given":"Eric J.","family":"Small","sequence":"first","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Frohlich","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bok","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Grossfeld","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinovi","family":"Rozenblat","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wm. Kevin","family":"Kelly","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Corry","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Reese","sequence":"additional","affiliation":[{"name":"From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0506","unstructured":"Porterfield  H:   Survey of UsToo members and other prostate cancer patients to evaluate the efficacy and safety of PC-SPES.   Mol Urol 3:  333,1999-337,"},{"key":"R2-0506","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391201"},{"key":"R3-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00216-2"},{"key":"R4-0506","doi-asserted-by":"crossref","unstructured":"Pfeifer  BL,   Pirani  JF,   Hamann  SR,  et al:  PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer.   Br J Urology 85:  481,1999-485,","DOI":"10.1046\/j.1464-410x.2000.00476.x"},{"key":"R5-0506","doi-asserted-by":"crossref","unstructured":"de la Taille  A,   Hayek  OR,   Buttyan  R,  et al:  Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer:   A preliminary investigation on human cell lines and patients.   Br J Urology 84:  845,1999-850,","DOI":"10.1046\/j.1464-410x.1999.00285.x"},{"key":"R6-0506","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(94)90121-X"},{"key":"R7-0506","unstructured":"Chen  X,   Han  R:   Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(alpha)pyrene.   Chin Med Sci J 10:  16,1995-19,"},{"key":"R8-0506","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-959748"},{"key":"R9-0506","doi-asserted-by":"crossref","unstructured":"Okada  K,   Tmura  Y,   Yamamoto  M,  et al:  Identification of antimicrobial and antioxidant constituents from licorice of Russian and Xinjiang origin.   Chem Pharm Bull Tokyo 37:  252,1989-258,","DOI":"10.1248\/cpb.37.2528"},{"key":"R10-0506","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-958126"},{"key":"R11-0506","unstructured":"Yun  TK,   Choi  SY:   Preventive effect of ginseng intake against various human cancers:   A case-control of 1987 pairs.   Cancer Epidemiol Biomarkers Prev 4:  401,1995-408,"},{"key":"R12-0506","unstructured":"Yun  TK,   Yun  YS,   Han  IW:   Anticarcinogenic effect of long-term oral administration of red ginseng on newborn mice exposed to various chemical carcinogens.   Cancer Detect Prev 6:  515,1983-525,"},{"key":"R13-0506","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00102-5"},{"key":"R14-0506","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.18.1197"},{"key":"R15-0506","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.17.635"},{"key":"R16-0506","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.57.894"},{"key":"R17-0506","doi-asserted-by":"crossref","unstructured":"Shang  J,   Wang  G,   Li  H,  et al:  Antitumor active protein-containing glycans from the Chinese mushroom songshan lingzhi, Ganoderma tsugae mycelium.   Biosci Biotechnol Biochem 58:  1202,1997-1205,","DOI":"10.1271\/bbb.58.1202"},{"key":"R18-0506","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.12.118"},{"key":"R19-0506","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X95000109"},{"key":"R20-0506","doi-asserted-by":"crossref","unstructured":"Tanaka  S,   Ko  K,   Kino  K,  et al:  Complete amino acid sequence of an immunomodulatory protein, ling Zhi-8:   An immunomodulator from a fungus, Ganoderma lucidum, having similarity to immunoglobulin variable regions.   J Biol Chem 264:  16272,1989-16377,","DOI":"10.1016\/S0021-9258(19)84715-4"},{"key":"R21-0506","doi-asserted-by":"publisher","DOI":"10.1042\/bj2820883"},{"key":"R22-0506","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1996.tb03155.x"},{"key":"R23-0506","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(94)90184-8"},{"key":"R24-0506","doi-asserted-by":"crossref","unstructured":"Hsieh  T,   Chen  SS,   Wang  X,  et al:  Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES.   Biochem Mol Biol Int 42:  535,1997-544,","DOI":"10.1080\/15216549700202941"},{"key":"R25-0506","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(20000215)42:3<163::AID-PROS1>3.0.CO;2-W"},{"key":"R26-0506","doi-asserted-by":"crossref","unstructured":"Tiwari  RK,   Geliebter  J,   Garikapaty  VP,  et al:  Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer.   Int J Oncol 14:  713,1999-719,","DOI":"10.3892\/ijo.14.4.713"},{"key":"R27-0506","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"R28-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(99)00028-8"},{"key":"R29-0506","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391504"},{"key":"R30-0506","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.275"},{"key":"R31-0506","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(72)90048-0"},{"key":"R32-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00017-9"},{"key":"R33-0506","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.382"},{"key":"R34-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00173-3"},{"key":"R35-0506","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301283280406"},{"key":"R36-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68943-4"},{"key":"R37-0506","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391210"},{"key":"R38-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62089-5"},{"key":"R39-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45620-5"},{"key":"R40-0506","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2250"},{"key":"R41-0506","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00008-9"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.21.3595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:35:47Z","timestamp":1653514547000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.21.3595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11,1]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2000,11,1]]}},"alternative-id":["10.1200\/JCO.2000.18.21.3595"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.21.3595","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11,1]]}}}